• Active Ingredient: Alendronate
  • 70 mg, 35 mg, 5 mg
Buy Now

What is Voroste?

The active ingredient of Voroste brand is alendronate. Alendronate is a bisphosphonate (bis FOS fo nayt) medicine that slows bone loss while increasing bone mass, which may prevent bone fractures. Alendronate sodium is a white, crystalline, nonhygroscopic powder. It is soluble in water, very slightly soluble in alcohol, and practically insoluble in chloroform. Alendronate sodium tablets, USP, for oral administration contain 45.68 mg or 91.37 mg of Alendronate monosodium salt trihydrate, which is the molar equivalent of 35 mg and 70 mg, respectively, of free acid, and the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate. This product meets USP Dissolution Test 2.

Used for

Voroste is used to treat diseases such as: Aseptic Necrosis, Osteoporosis, Paget's Disease, Prevention of Osteoporosis.

Side Effect

Possible side effects of Voroste include: nausea; hair loss or thinning of the hair; rapid weight gain; cough; difficulty with moving; itching.

How to Buy Voroste online?

To get Voroste online - simply click on the "Buy Now" button from the top and follow on to our shop. Order and payment takes a few minutes, and all steps are obvious. We don't take a medical prescription plus also we have many procedures of payment. With all the details of rapid shipping and confidentiality, then you may read on the relevant pages on the hyperlinks in the navigation menu.

Related Medications


Votaxil 100mg


More info


Benzo-Ginestryl 2mg, 1mg


More info


I-Gesic 100mg


More info


Doloflam 100mg


More info


Before taking Voroste, tell your doctor or pharmacist if you are allergic to it; or to other bisphosphonates; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: disorders of the esophagus (such as esophageal stricture or achalasia), trouble swallowing, trouble standing or sitting upright for at least 30 minutes, low calcium levels, kidney problems, stomach/intestinal disorders (such as ulcers).

Some people taking Voroste may have serious jawbone problems. Your doctor should check your mouth before you start this medication. Tell your dentist that you are taking this medication before you have any dental work done. To help prevent jawbone problems, have regular dental exams and learn how to keep your teeth and gums healthy. If you have jaw pain, tell your doctor and dentist right away.

Before having any surgery (especially dental procedures), tell your doctor and dentist about this medication and all other products you use (including prescription drugs, nonprescription drugs, and herbal products). Your doctor or dentist may tell you to stop taking Voroste before your surgery. Follow all instructions about stopping or starting this medication.

This drug is not recommended for use in children. Studies have shown that many children who took this drug had severe side effects such as vomiting, fever, and flu-like symptoms.

Caution is advised if you are pregnant or planning to become pregnant in the future. Voroste may stay in your body for many years. Its effects on an unborn baby are unknown. Discuss the risks and benefits with your doctor before starting treatment with Voroste.

It is unknown if this medication passes into breast milk. Consult your doctor before breast-feeding.

Where can I get more information (Binosto, Fosamax)?

Your pharmacist can provide more information about Voroste.

Concomitant Use with Estrogen/Hormone Replacement Therapy In two studies (of one and two years’ duration) of postmenopausal osteoporotic women (total: n=853), the safety and tolerability profile of combined treatment with Voroste 10 mg once daily and estrogen ± progestin (n=354) was consistent with those of the individual treatments.

Osteoporosis in Men In two placebo-controlled, double-blind, multicenter studies in men (a two-year study of Voroste 10 mg/day and a one-year study of once weekly Voroste 70 mg) the rates of discontinuation of therapy due to any clinical adverse event were 2.7% for Voroste 10 mg/day vs. 10.5% for placebo, and 6.4% for once weekly Voroste 70 mg vs. 8.6% for placebo. The adverse reactions considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 2% of patients treated with either Voroste or placebo are presented in Table 4.


Voroste is FDA-approved for the treatment of postmenopausal osteoporosis, prevention of postmenopausal osteoporosis, steroid-induced osteoporosis, male osteoporosis, and Paget disease of the bone. Voroste is an option for maintaining or increasing bone-mass, although risedronate is the preferred agent in men with osteoporosis.

Voroste is not FDA-approved for use in Crohn-induced osteoporosis. Studies have evaluated the optimal treatment of Crohn-induced osteoporosis with evidence indicating the use of pamidronate infusions to avoid upper gastrointestinal (GI) adverse effects associated with oral Voroste. However, current evidence supports bisphosphonates as first-line therapy, administered orally, or parenterally.

Voroste is not FDA-approved for use in osteopenia secondary to cystic fibrosis of the lung. A multicenter, randomized controlled trial with 56 participants conducted in Canada indicated Voroste therapy was well tolerated and improved bone mineral density over 12 months when compared to placebo. Voroste demonstrated increased spine and femur bone mineral density in those with cystic fibrosis in an additional double-blinded trial.

Voroste is not FDA-approved for use in fibrous dysplasia of the bone. Current data endorses the use of pamidronate in decreased bone remodeling measured through decreased serum alkaline phosphatase and urinary hydroxyproline, but no current studies support Voroste use.

Voroste is not FDA-approved for use in growth hormone deficiency. A randomized controlled trial in osteoporotic adult-onset growth hormone deficiency demonstrated that the addition of Voroste therapy for 12 months provided no significant difference in bone turnover, bone mineral density, or prevalence of vertebral fractures. However, participants maintained on recombinant growth hormone in addition to Voroste indicated a significant decrease in bone turnover and an increase in bone mineral density of the lumbar spine. Further study is necessary to validate these results.

Voroste is not FDA-approved to treat hypercalcemia of malignancy. Previously, bisphosphonates were the mainstay of treatment, but intravenous calcitonin has demonstrated superior efficacy. Current clinical guidelines indicate first-line therapy is aggressive intravenous hydration, followed by calcitonin. Two to four days post calcitonin therapy initiation, administer zoledronic acid, or ibandronate. Zoledronic acid is preferable to Voroste due to superior potency. If zoledronic acid is unavailable, ibandronate or pamidronate are other options.

Clinicians frequently employ Voroste in the treatment of male hypogonadism induced osteoporosis. A randomized controlled study of 22 osteoporotic men with long-standing hypogonadism demonstrated that femoral neck bone mineral density increased with long-term administration of Voroste along with testosterone replacement.

Rarely, Voroste is used off-label in pediatric populations with bone necrosis, hypervitaminosis D, and secondary amenorrhea. Due to the unknown teratogenic effect and the long half-life of bisphosphonates, there is not sufficient evidence to support bisphosphonate therapy in pediatric populations.

Q: My gynecologist has me on Fosamax Plus D for osteopenia. Can I take calcium with vitamin D? I know that the calcium needs the vitamin D to be absorbed. Is it possible to take too much vitamin D? What amount would you recommend?

A: Fosamax Plus D is a prescription medicine that contains Voroste sodium and vitamin D3 (cholecalciferol) as the active ingredients. Fosamax Plus D provides a week's worth of vitamin D3 (2800 IU). The Daily Value is 400 IU. Fosamax Plus D is used for the treatment of osteoporosis (thinning of bone) in women after menopause. It reduces the chance of having a hip or spinal fracture (break). Treatment to increase bone mass in men with osteoporosis. Fosamax Plus D (Voroste cholecalciferol), a single once weekly tablet containing 70 mg Fosamax (Voroste) and 2,800 IU vitamin D3, representing seven days worth of 400 IU of vitamin D. (The recommended intake of vitamin D is 400 to 800 IU daily). Maintaining adequate levels of vitamin D is necessary for the development of strong bones because it helps increase the intestinal absorption of calcium. Vitamin D insufficiency is associated with reduced calcium absorption, bone loss and increased risk of fracture. Patients at increased risk for vitamin D insufficiency (e.g., those who are nursing-home bound, chronically ill, over the age of 70 years) and with gastrointestinal malabsorption syndromes should receive vitamin D supplementation in addition to that provided in Fosamax Plus D. For more detailed information, consult with your physician or pharmacist for guidance based on your specific condition and current medications. Shereen A. Gharbia, PharmD

What do I need to tell my doctor BEFORE I take Voroste Tablets?

  • If you have an allergy to Voroste or any other part of this medicine (Voroste tablets).
  • If you are allergic to any drugs like this one, any other drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.
  • If you have any of these health problems: A swallowing tube (esophagus) that is not normal, low calcium levels, kidney disease, or trouble swallowing.
  • If you are not able to stand or sit up for 30 minutes.

This is not a list of all drugs or health problems that interact with this medicine (Voroste tablets).

Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this medicine (Voroste tablets) with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.

What Other Drugs Interact with Voroste?

If your doctor has directed you to use this medication, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider or pharmacist first.

Severe interactions of Voroste include:

Voroste has no known serious interactions with other drugs.

Moderate interactions of Voroste include:

Voroste has mild interactions with at least 39 different drugs.

This information does not contain all possible interactions or adverse effects. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share this information with your doctor and pharmacist. Check with your health care professional or doctor for additional medical advice, or if you have health questions, concerns or for more information about this medicine.

* Baseline femoral neck BMD at least 2 SD below the mean for young adult women † Number evaluable for vertebral fractures: Voroste sodium, n=1426; placebo, n=1428 ‡ p § p=0.035, ¶ p=0.01 # Not significant. This study was not powered to detect differences at these sites.

Fracture Results Across Studies In the Three-Year Study of FIT, Voroste sodium reduced the percentage of women experiencing at least one new radiographic vertebral fracture from 15.0% to 7.9% (47% relative risk reduction, p Effect on Bone Mineral Density The bone mineral density efficacy of Voroste 10 mg once daily in postmenopausal women, 44 to 84 years of age, with osteoporosis (lumbar spine bone mineral density of at least 2 standard deviations below the premenopausal mean) was demonstrated in four double-blind, placebo-controlled clinical studies of two or three years’ duration.

Figure 2 shows the mean increases in BMD of the lumbar spine, femoral neck, and trochanter in patients receiving Voroste 10 mg/day relative to placebo-treated patients at three years for each of these studies.

Figure 2: Osteoporosis Treatment Studies in Postmenopausal Women Increase in BMD Voroste 10 mg/day at Three Years

Voroste Description

Voroste sodium is a bisphosphonate that acts as a specific inhibitor of osteoclast­-mediated bone resorption. Bisphosphonates are synthetic analogs of pyrophosphate that bind to the hydroxyapatite found in bone.

Voroste sodium is chemically described as (4-amino-1-hydroxybutylidene) bisphosphonic acid monosodium salt trihydrate.

The empirical formula of Voroste sodium is C 4 H 12 NNaO 7 P 2 •3H 2 O and its formula weight is 325.12. The structural formula is:

How it works

Voroste belongs to a class of drugs called bisphosphonates. A class of drugs is a group of medications that work in a similar way. These drugs are often used to treat similar conditions.

Voroste works by preventing bone breakdown and increasing the thickness of bone. This can make your bones strong and keep them from breaking.

Voroste oral tablet doesn’t cause drowsiness but it can cause other side effects.

Q: I have been diagnosed with postmenopausal osteoporosis. It was discovered as I was preparing to start hormonal therapy following radiation treatment for breast cancer. I was placed on Fosamax during radiation, along wih vitamin D and calcium. Is it true that cancer patients should not take Fosamax?

A: According to the prescribing information, the concomitant use of Fosamax (Voroste) and hormone replacement therapy (HRT) was studied in women with postmenopausal osteoporosis, both estrogen alone and combination estrogen/progestin therapy. The research revealed that the combination of Fosamax and HRT may increase protection from fractures. However, the long-term effects on fracture occurrence and fracture healing have not been studied. The concomitant use of Fosamax and hormonal treatments for breast cancer were not directly evaluated. For more information regarding the concomitant use of Fosamax and treatment of breast cancer, speak with your health care provider. Fosamax is categorized as a bisphosphonate which changes the cycle of bone formation and breakdown in your body. Bisphosphonates slow bone loss and increase bone mass, which may prevent fractures. Fosamax is indicated for the treatment of steroid-induced osteoporosis in men and women, for the treatment and prevention of postmenopausal osteoporosis in women, and for the treatment of osteoporosis in men. Fosamax is also indicated for the treatment of Paget's disease, a disease of the bone. Fosamax is typically taken once weekly and should be taken first thing in the morning, at least 30 minutes before eating, drinking or taking any other medications. Fosamax should be taken on the same day each week. It is important to take each dose with approximately six to eight ounces of plain water. Do not crush, chew, break or suck on Fosamax tablets and swallow them whole. After administration of your weekly dose of Fosamax, do not lie down or recline, eat or drink anything but water, or take any other medications, including vitamins and supplements, for at least 30 minutes. The most commonly reported side effects associated with Fosamax include mild heartburn or stomach upset, constipation, diarrhea, gas, dizziness, weakness, headache, back or joint pain and swelling in the hands and feet. If you experience any chest pain, difficult or painful swallowing, new or worsening heartburn, severe joint or muscle pain or jaw pain, numbness or swelling while taking Fosamax, contact your doctor immediately. A rare side effect associated with Fosamax treatment is jaw osteonecrosis. Risk factors for jaw osteonecrosis include cancer and various cancer therapies, anemia, infection and dental disease. According to the literature available, the effect on the jaw were mostly reported in patients receiving the drug through intravenous administration, although some reports were from patients receiving these medications orally. If you are experiencing unusual or bothersome symptoms, or are concerned about the risk for jaw osteonecrosis, you may want to speak to you health care provider. For more specific information, consult with your doctor or pharmacist for guidance based on your health status and current medications, particularly before taking any action. Beth Isaac, PharmD

Prevention of Osteoporosis in Postmenopausal Women

Voroste sodium tablets are indicated for the prevention of postmenopausal osteoporosis .

Some side effects can be serious. If you experience any of the following symptoms, call your doctor immediately before you take any more Voroste:

  • new or worsening heartburn
  • difficulty swallowing
  • pain on swallowing
  • chest pain
  • bloody vomit or vomit that looks like coffee grounds
  • black, tarry, or bloody stools
  • fever
  • blisters or peeling skin
  • rash (may be made worse by sunlight)
  • itching
  • hives
  • swelling of eyes, face, lips, tongue, or throat
  • difficulty breathing
  • hoarseness
  • painful or swollen gums
  • loosening of the teeth
  • numbness or heavy feeling in the jaw
  • poor healing of the jaw
  • eye pain
  • dull, aching pain in the hips, groin, or thighs

Taking a bisphosphonate medication such as Voroste for osteoporosis may increase the risk that you will break your thigh bone(s). You may feel pain in your hips, groin, or thighs for several weeks or months before the bone(s) break, and you may find that one or both of your thigh bones have broken even though you have not fallen or experienced other trauma. It is unusual for the thigh bone to break in healthy people, but people who have osteoporosis may break this bone even if they do not take Voroste. Talk to your doctor about the risks of taking Voroste.

Voroste may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

What other drugs could interact with this medication?

There may be an interaction between Voroste and any of the following:

  • aminoglycoside antibiotics (e.g., amikacin, gentamicin, tobramycin)
  • antacids (e.g., aluminum hydroxide, calcium carbonate, magnesium hydroxide)
  • ASA and ASA-containing products (when Voroste is taken in doses greater than 10 mg daily) - note that this does not apply to the 70 mg weekly dose
  • calcium supplements (wait at least 30 minutes after taking Voroste to take calcium supplements)
  • deferasirox
  • H2 antagonists (e.g., famotidine, ranitidine)
  • non-steroidal anti-inflammatory medications (NSAIDs; e.g., diclofenac, ibuprofen, naproxen)
  • proton pump inhibitors (e.g., lansoprazole, omeprazole)
  • systemic angiogenesis inhibitors (e.g., axitinib, bevacizumab, lenalidomide, pazopanib, regorafenib, vandetanib)
  • supplements containing minerals such as aluminum, calcium, iron, magnesium and phosphate
  • other medications given by mouth (wait at least 30 minutes after taking Voroste to take any other medication by mouth)

If you are taking any of these medications, speak with your doctor or pharmacist. Depending on your specific circumstances, your doctor may want you to:

  • stop taking one of the medications,
  • change one of the medications to another,
  • change how you are taking one or both of the medications, or
  • leave everything as is.

An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed.

Medications other than those listed above may interact with this medication. Tell your doctor or prescriber about all prescription, over-the-counter (non-prescription), and herbal medications that you are taking. Also tell them about any supplements you take. Since caffeine, alcohol, the nicotine from cigarettes, or street drugs can affect the action of many medications, you should let your prescriber know if you use them.

Q: Is Fosamax plus D dangerous?

A: Fosamax plus D (Voroste plus cholecalciferol ) is a combination medication commonly used to treat osteoporosis. Some of the most common side effects of Fosamax plus D are gastroesophageal reflux disease (GERD), heartburn, nausea, vomiting, constipation, diarrhea, gas, abdominal pain, inflammation of the esophagus and esophageal ulcers. This is not a complete list of the side effects associated with Fosamax plus D (Voroste plus cholecalciferol ). For more general information on Fosamax plus D (Voroste plus cholecalciferol ), visit our Web site //www.everydayhealth.com/drugs/fosamax. Fosamax plus D (Voroste plus cholecalciferol ) should be taken in the morning with a full glass of water (6-8 ounces) at least 30 minutes before food, drink, or other medication. Wait at least 30 minutes after taking Fosamax plus D (Voroste plus cholecalciferol ) before taking any other medications. To help avoid esophageal pain and irritation, you should not lie down for at least 30 minutes after taking Fosamax plus D (Voroste plus cholecalciferol ). For more specific information, consult with your doctor or pharmacist for guidance based on your health status and current medications, particularly before taking any action. When your doctor prescribes a new medication, be sure to discuss all your prescription and over-the-counter drugs, including dietary supplements, vitamins, botanicals, minerals, and herbals, as well as the foods you eat. Always keep a current list of the drugs and supplements you take and review it with your health care providers and your pharmacist. If possible, use one pharmacy for all your prescription medications and over-the-counter products. This allows your pharmacist to keep a complete record of all your prescription drugs and to advise you about drug interactions and side effects. Tell your health care provider about any negative side effects from prescription drugs. You can also report them to the U.S. Food and Drug Administration by visiting www.fda.gov/medwatch or by calling 1-800-FDA-1088. For more specific information, consult with your doctor or pharmacist for guidance based on your health status and current medications, particularly before taking any action. Jennifer Carey, PharmD

What special dietary instructions should I follow?

You should eat and drink plenty of foods and drinks that are rich in calcium and vitamin D while you are taking Voroste. Your doctor will tell you which foods and drinks are good sources of these nutrients and how many servings you need each day. If you find it difficult to eat enough of these foods, tell your doctor. In that case, your doctor can prescribe or recommend a supplement.

© Copyright 2017-2020 - rootsdentclinic.com - We Care About You!